Opinion on Pharmaceuticals and Healthcare in Europe

Published within

« | ... | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

ESMO 2010: GlaxoSmithKline's BRAF inhibitor shows promising early efficacy

In October 2010, Datamonitor attended the 35th congress of the European Society of Medical Oncology, during which results were presented showing that GSK2118436, GlaxoSmithKline's BRAF kinase inhibitor, reduced the overall size of brain metastasis in almost all patients. However, as this success has so far been proved only in early phase trials, GSK must prove this efficacy through mature data.

Published By Datamonitor
18 Nov 2010
CommentWire
CommentWire

Merck & Co: CETP inhibitor calms class safety concerns with impressive results

Merck & Co. has announced that the DEFINE trial has met both its primary and secondary endpoints in lipid-level modification. Furthermore, safety data for anacetrapib dismissed a torcetrapib-like increase in cardiovascular events. The results allow Merck to progress into a large outcomes trial and will restore confidence in the CETP inhibitor class.

Published By Datamonitor
22 Nov 2010
CommentWire
CommentWire

RNAi: is the industry losing faith?

RNAi-based drugs were widely viewed as the next big thing after monoclonal antibodies; however, the initial wave of interest seems to be slowing down, largely due to financial constraints. Novartis and Roche recently ended their respective research in this field, highlighting the pharmaceutical industry's immediate need to boost its top line.

Published By Datamonitor
25 Nov 2010
CommentWire
CommentWire

EMA: draft biosimilar MAb guidelines will see case-by-case approvals

The European Medicines Agency's latest draft guidelines on monoclonal antibodies offer some flexibility for producers, but development costs are still expected to be high. With the instructions likely to be interpreted on a case-by-case basis, communication with the agency will be critical for success.

Published By Datamonitor
30 Nov 2010
Expert View
Expert View

Vaccines have re-emerged as growth drivers for the biopharmaceutical industry

Prior to 2000, vaccines were generally regarded as a commodity market with limited revenue opportunities. However, advances in vaccine technology, the launch of new vaccines, increased investment in research, a change of public opinion about vaccination, and more favorable legislation regarding vaccine injury compensation have contributed to their re-emergence as successful growth drivers.

Published By Datamonitor
01 Dec 2010
Expert View
Expert View

Vaccine market overview 2010

Five companies account for approximately 80% of total global vaccine sales: Sanofi Pasteur, Merck & Co., GlaxoSmithKline, Pfizer, and Novartis. The key reason for this oligopoly is the high barrier to entry for smaller players, which usually have limited manufacturing capacity, and may also lack the resources and the distribution networks required for vaccine development.

Published By Datamonitor
01 Dec 2010
CommentWire
CommentWire

Teva: promising oral drug to defend multiple sclerosis franchise against Gilenya

Following encouraging Phase III results, Teva's laquinimod is firmly in line to become the third approved oral treatment in relapsing-remitting multiple sclerosis. However, with the recent launch of the first oral multiple sclerosis therapy, Novartis's Gilenya, Teva will face a serious challenge in keeping hold of its market-leading multiple sclerosis share.

Published By Datamonitor
09 Dec 2010
Expert View
Expert View

Roche/Genentech/Biogen Idec: Rituxan delays need for new therapy in follicular lymphoma

New data show that immediate treatment with Rituxan provides an impressive reduction in follicular lymphoma progression rates. These results could lead to a change in the management of newly diagnosed asymptomatic follicular lymphoma patients and increased uptake of Rituxan in the seven major markets.

Published By Datamonitor
13 Dec 2010
CommentWire
CommentWire

Europe: proposal to push through the creation of a single EU patent divides opinion

The proposed "enhanced co-operation mechanism," if approved, would allow some member states to move forward on developing a single EU patent. This could reduce costs and improve competitiveness in the pharma industry. However, unrest could be created among EU member states as Italy and Spain do not agree with the proposal or the commission's translation plans for the patent.

Published By Datamonitor
16 Dec 2010
Expert View
Expert View

NICE maintains central role in UK value-based pricing approach as guidelines enter consultation

The UK's Department of Health has published its value-based pricing approach for medicines for consultation until March 2011. The proposed guidelines envisage different price thresholds for drugs based on the value that they deliver to the health service. While the cost watchdog's role would be changed, it would not be quite as diminished as first thought.

Published By Datamonitor
21 Dec 2010

« | ... | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | ... | » »|

No help is available.